Clinical Trials - ImmunoGen

CLINICAL TRIALS

We have a variety of ongoing clinical trials in different therapeutic areas, which are detailed below. If you have any questions about any of these trials, contact our Medical Affairs team via email medicalaffairs@immunogen.com or by phone (+1-781-895-0115).

ACUTE MYELOID LEUKEMIA (AML)
ClinicalTrials.gov Identifier: NCT04086264
IMGN632 (Pivekimab Sunirine) as a Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia
Status: Recruiting

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
ClinicalTrials.gov Identifier: NCT03386513
Study of IMGN632 (Pivekimab Sunirine) in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Status: Recruiting
More Information: https://immunogenclinicaltrials.com/bpdcn/

OVARIAN CANCER
ClinicalTrials.gov Identifier: NCT04296890
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA)
Status: Active, Not Recruiting

ClinicalTrials.gov Identifier: NCT04209855
A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)
Status: Recruiting

ClinicalTrials.gov Identifier: NCT05041257
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)
Status: Recruiting

ImmunoGen’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.